Find a Provider

Lynn M. Schuchter, MD Physician

Chief, Hematology Oncology, Department of Medicine
C. Willard Robinson Professor of Hematology-Oncology

Dr. Schuchter is a Penn Medicine employed physician.

About Dr. Lynn M. Schuchter

Recognized annually in Philadelphia Magazine's Top Docs issue from 2004 through 2015

Recognized by America's Top Doctors, 2007, 2008, 2010-2014

Recognized by Best Doctors in America 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Merkel Cell Carcinoma
    • Skin Cancer

Board Certification:

  • Internal Medicine, 1985
  • Medical Oncology, 1989

Conditions & Treatments:

  • Breast Cancer
  • clinical trials
  • melanoma
  • Melanoma
  • Melanoma
  • Non-Melanoma Skin Cancer
  • Skin Cancer

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Chicago Medical School
Residency: Michael Reese Hospital
Fellowship: Johns Hopkins Hospital


American Cancer Society, American Cancer Society, Philadelphia Division, American Medical Association, American Medical Women's Association, American Society of Clinical Oncology (ASCO), National College of Physicians, Philadelphia, Eastern Cooperative Oncology Group(ECOG), National Melanoma Research Foundation, National Melanoma Research Foundation, National Membership in National Scientific Review Panels: National Institutes of Health, National Society of Biological Therapy, Society of Melanoma Research,


Dr. Schuchter is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.


Selected Publications:

Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JD, Tsai KY, Flaherty KT, Sosman J, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Seuplveda AR: Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res. : 2015.

Gangadhar TC, Schuchter LM.: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA Oncol. 1 (4): 427-8,2015.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ.: Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist : 2015.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (7547): 373-7,2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res 21 (7): 1652-64,2015.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA 4th, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol 33 (3): 2015.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA Iiii, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol : 2014.

Glanz K, Volpicelli K, Jepson C, Ming ME, Schuchter LM, Armstrong K.: Effects of Tailored Risk Communications for Skin Cancer Prevention and Detection: The PennSCAPE Randomized Trial. Cancer Epidemiol Biomarkers Prev 24 (2): 2014.

Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X, Zhang H.: Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer. J Mol Biomark Diagn : 2014.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.: Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 32 (33): 3697-704,2014.

Academic Contact Info

Perelman Center for Advanced Medicine
South Pavilion, 6th Floor, Room 631

Philadelphia, PA 19104
Phone: (215) 662-4859
Fax: (215) 349-5866
Patient appointments: 800-789-PENN (7366)

Related Links